Yukari Manabe, MD

CRS:

JHU

Role:

Investigators

Position:

Investigator

Email:

ymanabe@jhmi.edu

As part of the Center for Global Health, Dr. Manabe is interested in rapid diagnostics suitable for the resource-limited settings particularly in sub-Saharan Africa (SSA). She began her career working on the basic science aspects of tuberculosis (TB) immunopathogenesis in comparative animal models of infection, particularly latency, reactivation, and immune reconstitution inflammatory syndrome (IRIS) in the rabbit model within the Johns Hopkins Center for Tuberculosis Research. In 2007, she was seconded to the Infectious Diseases Institute (IDI) at Makerere College of Health Sciences as the Associate Medical Laboratory Director of the College of American Pathologists certified Makerere University-Johns Hopkins University Clinical Core Lab to study antiretroviral associated TB and IRIS. She then became the Head of Research at the IDI in 2008 until 2012 where she built research capacity and infrastructure for training Ugandan investigators. Her research has focused on accuracy testing of various rapid, point-of-care diagnostics for HIV and related infectious diseases of clinical importance in SSA. She is also interested in studying the impact of various diagnostic interventions on disease detection and patient outcomes.

Dr. Yukari Manabe obtained her undergraduate degree from Yale University and her M.D. from Columbia University College of Physicians and Surgeons. After completing both her residency in Internal Medicine and fellowship in Infectious Diseases at Johns Hopkins Hospital, she joined the faculty in 1999.

  • NWCS 408, parent study A5274

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5350: Effects of Visbiome Extra Strength on Gut Microbiome...

Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...

Read More

A5253: Sensitivity and Specificity of Mycobacterium...

An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...

Read More

P2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate...

This study is currently on hold. The study is designed to characterize the pharmacokinetics of DLM using a model-based...

Read More

A5349: Rifapentine-containing treatment shortening regimens...

The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More